GoodRx (GDRX) Stock Price, News & Analysis

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings or view top-rated stocks.

19 brokers have issued 1 year target prices for GoodRx's shares. Their GDRX share price targets range from $4.50 to $14.00. On average, they expect the company's share price to reach $8.78 in the next year. This suggests a possible upside of 31.0% from the stock's current price.
View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts.

GoodRx's stock was trading at $6.70 at the beginning of the year. Since then, GDRX stock has increased by 0.0% and is now trading at $6.70.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GDRX earnings forecast.

GoodRx will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

GoodRx Holdings, Inc. (NASDAQ:GDRX) posted its quarterly earnings data on Thursday, February, 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The company had revenue of $196.64 million for the quarter, compared to the consensus estimate of $195.59 million. GoodRx had a negative net margin of 1.18% and a positive trailing twelve-month return on equity of 2.45%.

ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include WisdomTree Growth Leaders Fund (PLAT) and Global X Telemedicine & Digital Health ETF (EDOC).IQ Chaikin U.S. Small Cap ETF (CSML).

GoodRx updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $800.0 million-$800.0 million, compared to the consensus revenue estimate of $790.5 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

GoodRx (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

GoodRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Counterpoint Mutual Funds LLC (0.01%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek.
View institutional ownership trends.

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.